Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

Genentech Procures Amphora Oncology Program

  • Genentech reported that it will purchase Amphora's entire program for an unnamed early-stage oncology target with the potential to treat multiple oncology indications.

    The company thus acquired all the intellectual property for the program, including the preclinical lead and several backup series.

    “Amphora's drug discovery engine has produced and is continuing to produce extremely high quality new products,” points out C. Nicholas Hodge, Ph.D., Amphora's CSO and founder. “Amphora has shown that it is capable of moving programs quickly and cost-effectively from screening to proof-of-concept with surprisingly low attrition rates.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »